Company News 

Silence Therapeutics gets into in bed with AstraZeneca

Silence Therapeutics gets into in bed with AstraZeneca

Near-term prospects for most industries may have deteriorated, but we could witness a step-up in interest for biotech stocks down the line. One of the strongest risers in trading on 25 March was Silence Therapeutics (SLN), a specialist in RNA (ribonucleic acid) therapies - a clinical approach which aims to stifle (or ‘silence’) the production of disease-causing proteins in the body through inhibiting genes in the human genome.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now